证券日报网讯12月29日，诚益通（300430）在互动平台回答投资者提问时表示，公司脑机接口业务方 面，近期公司控股子公司北京脑连科技有限公司获得了"脑电采集装置和脑电采集设备"发明专利，同 时，公司也在抓紧推进脑电采集相关医疗器械产品注册证的申报工作，2026年将取得相关注册证书，请 关注公司披露信息及脑连科技公众号进展。 ...

Group 1 - Gold and silver prices have surged in December, with silver prices more than doubling this year, surpassing gold [1] - Silver futures on the New York Mercantile Exchange broke the $80 per ounce mark, exceeding the price of a barrel of crude oil, which closed at $56.74 [1] - The demand for silver remains strong from various sectors, including jewelry, medical devices, electric vehicles, and particularly solar panel manufacturing, which consumes nearly 30% of the global annual silver production [1] Group 2 - Notable investor Peter Schiff warns of an impending historic crisis in the U.S. economy, attributing rising inflation and precious metal prices to a loss of confidence in U.S. Treasury bonds and the dollar [2] - Schiff indicates that significant increases in gold prices signal a lack of confidence in the dollar, leading investors to prefer gold over U.S. bonds [2] - He predicts that daily increases in gold prices exceeding $100 will become common, with expectations of a $200 increase in a single day soon [2]

证券日报网讯 12月29日，楚天科技发布公告称，公司第六届董事会第五次会议审议通过《关于对可转 换公司债券募投项目重新论证并暂缓实施的议案》《关于使用部分暂时闲置募集资金进行现金管理的议 案》《关于变更注册资本、增加经营范围及修订并办理工商登记的议案》等多项议案。 （编辑 任世碧） ...

转自：新华财经 12月29日，海尔康养赣州科创园二期开园仪式于江西章贡高新区举行。该园区是赣州对标深圳、落地见 效的"工改工"城市更新标杆项目，其落成，是地方政府与领军企业协同推进高质量发展、布局未来健康 产业的重要成果，更是海尔康养构建全场景健康生态、推动产业创新升级的战略性布局。 作为医药健康产业新高地，近年来，赣州市以超常规战略擎举医药健康产业。海尔康养家庭医疗大健康 类产品生产基地的跨越式成长正是这一战略高效实施的缩影。从2021年落户赣州，仅用6个月完成一期 建设，到如今年销售额突破7亿元，扩产二期，海尔康养科创园以实绩生动诠释了产城融合的高效路 径。 政企协同 共创产城融合标杆 据悉，海尔康养赣州科创园二期总占地约23000㎡，配备10大医疗设备专业检测实验室、MES数智系 统、海康AGVCTU智能仓储及智能SOP部件级追溯等多个智能制造应用，汇聚400余项自主研发专利、4 大质量体系认证，拥有10个AI+5G物联技术智能制造应用场景，预计年产达到600万台。 值得关注的是，作为集研发、生产、营销、服务、物流于一体的全链条智慧园区，项目创新构建"上下 楼就是上下游"的垂直产业生态，从产学研到智能制 ...

Core Viewpoint - The company, Qiming Medical, is divesting a minority stake in Valgen Holding Corporation to focus on its core business and improve financial flexibility through the sale of non-core investments [1] Group 1: Transaction Details - Qiming Medical (Hong Kong) Limited has entered into a share transfer agreement with Broncus China Holding Corporation to sell shares for a total consideration of $15 million, representing approximately 1.05% of the total issued shares of Valgen Holding Corporation as of the announcement date [1] - Valgen Holding Corporation is a Cayman Islands registered company primarily engaged in providing systemic solutions for mitral and tricuspid regurgitation [1] Group 2: Strategic Rationale - The company aims to reallocate resources to develop its core products and support long-term business growth by streamlining its investment portfolio [1] - The board believes that prudent capital management, including this divestment, will enhance the company's sustainable development and strengthen shareholder returns [1]

该股最近90天内共有11家机构给出评级，买入评级9家，增持评级2家；过去90天内机构目标均价为 39.71。 证券之星消息，截至2025年12月29日收盘，开立医疗(300633)报收于26.33元，下跌0.83%，换手率 0.5%，成交量2.18万手，成交额5753.51万元。 12月29日的资金流向数据方面，主力资金净流出482.96万元，占总成交额8.39%，游资资金净流入307.6 万元，占总成交额5.35%，散户资金净流入175.36万元，占总成交额3.05%。 近5日资金流向一览见下表： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营 ...

Core Viewpoint - Qiming Medical-B (02500) announced a share transfer agreement where Qiming Medical (Hong Kong) Limited will sell shares to Broncus China Holding Corporation for $15 million, representing approximately 1.05% of the total issued shares of Valgen Holding Corporation as of the announcement date [1] Group 1: Investment Details - The transaction involves the sale of shares for a total consideration of $15 million [1] - The investment company Valgen Holding Corporation is registered and incorporated under Cayman Islands law and primarily provides systemic solutions for mitral and tricuspid regurgitation [1] Group 2: Strategic Focus - The company aims to reallocate resources to develop its core products and support long-term business growth by streamlining its investment portfolio [1] - As a minority financial investor in Valgen, the sale represents an appropriate opportunity for the group to monetize its investment [1] - By divesting non-core business investments, the group expects to strengthen its cash flow, improve its working capital position, enhance overall financial flexibility, and facilitate resource reallocation to its core business [1] Group 3: Capital Management - The board believes that prudent capital management, including this sale, is beneficial for ensuring the sustainable development of the group and enhancing shareholder returns [1]

（编辑 楚丽君） 证券日报网讯 12月29日，威高骨科发布公告称，公司2025年12月29日在上海召开第三次临时股东会， 审议通过《关于变更部分募投项目暨收购苏州杰思拜尔医疗科技有限公司股权并对其增资的议案》《关 于选举李进取先生为第三届董事会非独立董事的议案》。 ...

证券之星消息，截至2025年12月29日收盘，大博医疗(002901)报收于48.32元，下跌1.67%，换手率 0.56%，成交量1.62万手，成交额7864.64万元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 12月29日的资金流向数据方面，主力资金净流出949.84万元，占总成交额12.08%，游资资金净流入 134.16万元，占总成交额1.71%，散户资金净流入815.68万元，占总成交额10.37%。 近5日资金流向一览见下表： 大博医疗2025年三季报显示，前三季度公司主营收入18.76亿元，同比上升22.69%；归母净利润4.25亿 元，同比上升77.03%；扣非净利润3.46亿元，同比上升63.99%；其中2025年第三季度，公司单季度主营 收入6.66亿元，同比上升17.82%；单季度归母净利润1.8亿元，同比上升77.49%；单季度扣非净利润1.23 亿元，同比上升38.44%；负债率24.53%，投资收益580.87万元，财务费用-2387.47万元，毛利率 71.23%。大博医疗（002901）主营业 ...

Group 1 - The core point of the article is that Hongri Pharmaceutical (300026.SZ) announced that its wholly-owned subsidiary, Tianjin Chaosi Medical Equipment Co., Ltd., received a medical device registration certificate from the Tianjin Municipal Drug Administration for a multi-parameter remote monitoring system [1]